<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00537316</url>
  </required_header>
  <id_info>
    <org_study_id>P04807</org_study_id>
    <nct_id>NCT00537316</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)</brief_title>
  <official_title>Comparison of the Efficacy and Safety of Infliximab, as Monotherapy or in Combination With Azathioprine, Versus Azathioprine Monotherapy in Moderate to Severe Active Ulcerative Colitis (Part 1) Comparison of Maintenance Versus Intermittent Infliximab Treatment in Maintaining Remission: A Follow-Up of Efficacy and Safety (Part 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 of this study is a 3-arm, randomized, active-controlled, parallel-group, multicenter,
      double-blind, double-dummy, 16-week study to compare the efficacy and safety of infliximab
      (IFX), as monotherapy or in combination with azathioprine (AZA) versus AZA monotherapy in
      adults with moderate to severe active ulcerative colitis (UC). Participants who qualify at
      the Baseline Visit will be eligible to be randomized to one of the three active treatment
      groups.

      Participants in the IFX/AZA combination therapy and IFX monotherapy cohorts will receive IFX
      infusions at Weeks 0, 2, and 6 and daily oral AZA/placebo, respectively; participants in the
      AZA cohort will receive daily oral AZA and placebo infusions at Weeks 0, 2, and 6. At Week 8,
      all participants will be evaluated for response.

      Participants responding to IFX treatment at Week 8, either as monotherapy or in combination
      with AZA, will receive one more IFX infusion at Week 14; non-responders to IFX therapy will
      receive placebo infusions at Weeks 8 and 10 and one additional IFX infusion at Week 14.

      Participants responding to AZA monotherapy at Week 8 will continue on AZA therapy and receive
      one placebo infusion at Week 14; nonresponders to AZA will be eligible to receive IFX at
      Weeks 8, 10, and 14.

      Part 2: Participants in remission on IFX monotherapy or IFX/AZA treatment at Week 16 will be
      randomized to either maintenance or intermittent open-label IFX treatment; randomization will
      be stratified based on oral AZA/placebo treatment in Part 1. Oral AZA/placebo treatment will
      continue to be double-blinded. All participants will continue to receive oral AZA/ placebo
      for the duration of the study.

      Participants randomized to maintenance IFX treatment will receive scheduled IFX infusions
      every 8 weeks beginning at Week 22 (Week 6 for direct entry). If participants lose response,
      or if treatment has to be discontinued because of an adverse event, these participants are
      considered treatment failures, and should be followed up for safety at the scheduled 6-month
      visits (Weeks 38, 62, and 94 [Weeks 22, 46, and 78 for direct entry]). These participants
      will receive standard of care per their personal physician.

      Participants randomized to intermittent IFX treatment will be evaluated every 8 weeks.
      Participants will receive IFX only upon relapse of disease. Treatment with IFX will be
      initiated at Weeks 0, 2, and 6 of the individual treatment cycle and will continue every 8
      weeks until remission is regained. Throughout the study, individual treatment cycles will be
      repeated whenever a subject relapses.

      In addition, to facilitate enrollment into Part 2, participants who received treatment
      outside of Part 1 and who are in remission on IFX with or without AZA/6-mercaptopurine (6-MP)
      will be allowed to enter directly into Part 2. In the Czech Republic, direct entry into Part
      2 of the study is not allowed.

      A higher than expected incidence of serious infusion reactions observed in the intermittent
      treatment arm of another study (Protocol P04563, NCT0358670) conducted in participants with
      moderate to severe psoriasis resulted in the termination of that study. Based on the
      similarities in study design between the intermittent treatment arm of P04563 and the
      intermittent treatment arm of Part 2 of this study, enrollment to Part 2 of this study was
      put on hold, for precautionary reasons. At the same time, all participants already enrolled
      in the intermittent treatment arm of Part 2 were asked to discontinue from the trial. In
      October 2009, a decision was made by the sponsor to terminate the whole study (Part 1 and 2).
      At that time, participants enrolled in Part 1 of the study were allowed to complete their
      treatment up to Week 16.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Infusion reactions during re-induction cycles after a period of no treatment in another study
    [P04563, NCT0358670]
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants in Steroid-free Remission at Week 16</measure>
    <time_frame>16 weeks</time_frame>
    <description>Steroid-free remission is defined as a total Mayo score of 2 points or lower, with no individual sub-score exceeding 1 point, without the use of corticosteroids. The total Mayo score consists of the following 4 sub-scores: stool frequency, rectal bleeding, findings of endoscopy (sigmoidoscopy), and physician's global assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Remission Rate During Part 2 of the Study</measure>
    <time_frame>up to Week 94 (Week 78 for direct entry)</time_frame>
    <description>Due to the early termination of this study, evaluations of efficacy were not conducted for Part 2 of the study (Week 38 through Week 94 [Week 22 through Week 78 for direct entry]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants in Response at Weeks 8 and 16</measure>
    <time_frame>Weeks 8 and 16</time_frame>
    <description>Response at Week 8 is defined as a decrease in the partial Mayo score of ≥1 point. Response at Week 16 is defined as a decrease in total Mayo score of ≥3 points and at least 30% lower than baseline Mayo score. The partial Mayo score consists of the following 3 sub-scores: stool frequency, rectal bleeding, and physician's global assessment. The total Mayo score consists of the following 4 sub-scores: stool frequency, rectal bleeding, findings of endoscopy (sigmoidoscopy), and physician's global assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Mucosal Healing at Week 16</measure>
    <time_frame>16 weeks</time_frame>
    <description>Mucosal healing was defined as a Mayo endoscopy score of 0 or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Are in Steroid-free Remission During Part 2 of the Study</measure>
    <time_frame>Weeks 38, 62 &amp; 94 (Weeks 22, 46 and 78 for direct entry)</time_frame>
    <description>Due to the early termination of this study, evaluations of efficacy were not conducted for Part 2 of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Mucosal Healing During Part 2 of the Study</measure>
    <time_frame>Weeks 38, 62 and 94 (Weeks 22, 46 and 78 for direct entry)</time_frame>
    <description>Due to the early termination of this study, evaluations of efficacy were not conducted for Part 2 of the study</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Infliximab (IFX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: IFX 5 mg/kg of body weight intravenous (IV) infusions was to be administered at Weeks 0, 2, and 6 and placebo to AZA was to be taken orally every day for 16 weeks. Responders to IFX at Week 8, were to receive one more IFX infusion at Week 14; non-responders to IFX were to receive placebo IFX infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks [q8w]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azathioprine (AZA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AZA 2.5 mg/kg of body weight orally every day for 16 weeks. Responders to AZA monotherapy at Week 8 were to continue on AZA therapy and receive one placebo infusion at Week 14; non-responders to AZA at Week 8 would be eligible to receive an IFX infusion at Weeks 8, 10, and 14. Participants in steroid-free remission at Week 16 were to continue on AZA monotherapy and were to be followed up for safety in Part 2. Participants who experienced a relapse of disease after Week 16 were to continue daily AZA monotherapy and receive 3 infusions of IFX (induction therapy at Weeks 0, 2, and 6) followed by infusions every 8 weeks (maintenance therapy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFX/AZA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFX 5 mg/kg of body weight IV infusions at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally every day for 16 weeks. Responders to IFX/AZA at Week 8 were to receive one more IFX infusion at Week 14; non-responders to IFX/AZA were to receive placebo infusions at Weeks 8 and 10 and one additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks [q8w]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance IFX/AZA (during Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to maintenance IFX/AZA in Part 2 of the study were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) plus AZA 2.5 mg/kg of body weight daily. Four participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance IFX (during Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to maintenance IFX were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) in Part 2 of the study. Placebo to AZA therapy was to continue as allocated in Part 1 of the study. All participants were from Part 1 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent IFX/AZA (during Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to intermittent IFX/AZA were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained) plus AZA 2.5 mg/kg of body weight daily in Part 2 of the study. Three participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent IFX (during Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to intermittent IFX were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained). Placebo to AZA therapy was to continue as allocated in Part 1 of the study. One participant was from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab (IFX)</intervention_name>
    <description>IFX intravenous (IV) infusion dosed at 5mg/kg of body weight</description>
    <arm_group_label>Infliximab (IFX)</arm_group_label>
    <arm_group_label>IFX/AZA</arm_group_label>
    <arm_group_label>Maintenance IFX/AZA (during Part 2)</arm_group_label>
    <arm_group_label>Maintenance IFX (during Part 2)</arm_group_label>
    <arm_group_label>Intermittent IFX/AZA (during Part 2)</arm_group_label>
    <arm_group_label>Intermittent IFX (during Part 2)</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine (AZA)</intervention_name>
    <description>AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day</description>
    <arm_group_label>Azathioprine (AZA)</arm_group_label>
    <arm_group_label>IFX/AZA</arm_group_label>
    <arm_group_label>Maintenance IFX/AZA (during Part 2)</arm_group_label>
    <arm_group_label>Intermittent IFX/AZA (during Part 2)</arm_group_label>
    <other_name>Imuran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Azathioprine</intervention_name>
    <description>Placebo to AZA tablet orally every day</description>
    <arm_group_label>Infliximab (IFX)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>Placebo to IFX intravenous (IV) infusion</description>
    <arm_group_label>Infliximab (IFX)</arm_group_label>
    <arm_group_label>Azathioprine (AZA)</arm_group_label>
    <arm_group_label>IFX/AZA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must be &gt;=21 years of age at the time of informed consent, of either sex, and of any
             race;

          -  must have endoscopic evidence of UC, as determined by sigmoidoscopy, within 14 days
             prior to Baseline;

          -  must have a total Mayo score of 6 to 12 points at Baseline;

          -  must have responded inadequately to corticosteroid treatment (ie, the last or current
             UC flare did not respond adequately to a standard course of corticosteroids) with or
             without 5 aminosalicylic acid (5-ASA);

          -  must be off corticosteroids or on a stable dose of corticosteroid for at least 2 weeks
             prior to enrollment. The maximal daily dose of corticosteroid at Baseline must not
             exceed the equivalent of 30 mg of prednisone;

          -  must be naïve to infliximab and other tumor necrosis factor-alpha (TNF-α) antagonists;

          -  must be either naïve to AZA/6-MP or have not received AZA/6-MP for at least 3 months
             before enrollment in the study;

          -  considered eligible according to the following tuberculosis (TB) screening criteria:

               -  have no history of latent or active TB prior to Screening;

               -  have no signs or symptoms suggestive of active TB upon medical history and/or
                  physical examination;

               -  have had no recent close contact with a person with active TB or, if there has
                  been such contact, will be referred to a physician specializing in TB to undergo
                  additional evaluation and, if warranted, receive appropriate treatment for latent
                  TB prior to or simultaneously with the first administration of IFX;

               -  within 1 month prior to the first administration of infliximab, either have
                  negative tuberculin skin test OR have a newly identified positive tuberculin test
                  during Screening in which active TB has been ruled out, and for which appropriate
                  treatment for latent TB has been initiated either prior to or simultaneously with
                  the first administration of IFX.

               -  must have a chest X-ray (posterior-anterior and lateral views), taken within 3
                  months prior to the first administration of study agent and read by a qualified
                  radiologist, with no evidence of current active TB or old active TB;

          -  have had UC for more than 10 years should have had a full colonoscopy within 2 years
             prior to Screening for the surveillance of dysplasia;

          -  screening and Baseline clinical laboratory tests (complete blood count [CBC] and blood
             chemistries) must be within predetermined parameters

          -  had been on antibiotics for the treatment of UC (eg, ciprofloxacin and metronidazole)
             must have been discontinued from them at least 3 weeks prior to Screening;

          -  must be free of any clinically significant condition or situation, other than UC that,
             in the opinion of the investigator, would interfere with the study evaluations or
             optimal participation in the study;

          -  willing and able to adhere to the study visit schedule and other protocol
             requirements;

          -  capable of providing written informed consent, which must be obtained prior to
             conducting any protocol-specified procedures;

          -  women of child-bearing potential and all men must agree to use a medically accepted
             method of contraception prior to screening, while receiving protocol-specified
             medication, and for 6 months after stopping the medication. Acceptable methods of
             contraception include condoms (male or female) with or without a spermicidal agent,
             diaphragm or cervical cap with spermicide, medically prescribed intrauterine device
             (IUD), oral or injectable hormonal contraceptive, and surgical sterilization (eg,
             hysterectomy or tubal ligation). Women of child-bearing potential who are not
             currently sexually active must agree to use a medically accepted method of
             contraception should they become sexually active while participating in the study;

          -  female participants of childbearing potential must have a negative serum pregnancy
             test (beta-human chorionic gonadotropin) at Screening and a negative urine pregnancy
             test at Baseline.

        Exclusion Criteria:

          -  have severe extensive colitis as evidenced by:

               -  investigator judgment that the participant is likely to require colectomy within
                  12 weeks of Baseline

        OR

          -  at least 4 of these symptoms at Screening or Baseline visits, as follows:

               -  diarrhea with &gt;=6 bowel movements/day with macroscopic blood in stool;

               -  focal severe or rebound abdominal tenderness;

               -  persistent fever (&gt;=37.5 degrees C) for at least 3 days prior to baseline;

               -  tachycardia (&gt;100 beats/minute);

               -  hemoglobin &lt;8.5 g/dL (5.3 mM/L).

                    -  require, or are required within the 2 months prior to baseline, surgery for
                       active gastrointestinal bleeding, peritonitis, intestinal obstruction, or
                       intra-abdominal or pancreatic abscess requiring surgical drainage or other
                       conditions possibly confounding the evaluation of disease activity;

                    -  have severe, fixed symptomatic stenosis of the large or small intestine;

                    -  have current evidence of colonic obstruction or history within the 6 months
                       prior to baseline, confirmed with objective radiographic or endoscopic
                       evidence of a stricture with resulting obstruction (dilation of the colon
                       proximal to the stricture on barium radiograph or an inability to traverse
                       the stricture at endoscopy);

                    -  have a history of colonic mucosal dysplasia;

                    -  presence on screening endoscopy of adenomatous colonic polyps, if not
                       removed prior to study entry, or history of adenomatous colonic polyps that
                       were not removed;

                    -  have the presence of a stoma;

                    -  have a history of extensive colonic resection that would prevent adequate
                       evaluation of clinical disease activity (eg, less than 30 cm of colon
                       remaining);

                    -  have had a positive stool culture for enteric pathogens, pathogenic ova or
                       parasites within 4 months prior to Baseline unless participant has received
                       treatment and had a negative stool examination 1 week or longer after the
                       end of treatment;

                    -  have a concomitant diagnosis of congestive heart failure (CHF), including
                       medically controlled asymptomatic subjects;

                    -  have had serious infections (eg, active hepatitis, pneumonia, or
                       pyelonephritis) within 2 months of Screening. Less serious infections (such
                       as acute upper respiratory tract infection [colds] or a simple urinary tract
                       infection) need not be considered as an exclusion at the discretion of the
                       investigator;

                    -  have had a nontuberculous mycobacterial infection or opportunistic infection
                       (eg, cytomegalovirus, Pneumocystis carinii, aspergillosis) within 6 months
                       prior to Screening;

                    -  have a known infection with human immunodeficiency virus (HIV) and/or
                       hepatitis B or hepatitis C;

                    -  have a history of a known allergy to murine proteins or allergy/sensitivity
                       to study drug or its excipients;

                    -  have current signs and symptoms of systemic lupus erythematosus, or severe,
                       progressive, or uncontrolled renal, hepatic, hematologic, endocrine,
                       pulmonary, cardiac, neurologic, or cerebral diseases;

                    -  have a known history of demyelinating disease suggestive of multiple
                       sclerosis or optic neuritis;

                    -  presence of a transplanted organ (with the exception of a corneal transplant
                       &gt;3 months prior to Screening);

                    -  have a history of lymphoproliferative disease including lymphoma, or signs
                       and symptoms suggestive of possible lymphoproliferative disease, such as
                       lymphadenopathy of unusual size or location (eg, nodes in the posterior
                       triangle of the neck, infra-clavicular, epitrochlear, or periaortic areas),
                       or splenomegaly;

                    -  have any current known malignancy or malignancy within 5 years prior to
                       Screening (except for squamous or basal cell carcinoma of the skin that has
                       been treated with no evidence of recurrence);

                    -  have poor tolerability of venipuncture or lack of adequate venous access for
                       required blood sampling and infusion of study drug during the study period;

                    -  have had a known substance abuse or dependency (drug or alcohol) within 3
                       years of Screening;

                    -  require chronic (&gt;=1 month) and frequent use (&gt;=3 days per week)of
                       nonsteroidal anti-inflammatory drugs (NSAIDs) except low-dose aspirin for
                       prevention of heart attacks, unstable angina, or transient ischemic attacks;

                    -  have other inflammatory diseases that might interfere with the evaluation of
                       the ulcerative colitis;

                    -  have a history of latent or active granulomatous infection, including TB,
                       histoplasmosis, or coccidioidomycosis, prior to Screening.

                    -  have had a Bacille Calmette-Guerin (BCG) vaccination within 12 months of
                       Screening.

                    -  have had a chest X-ray within the 3 months prior to the first administration
                       of study agent that shows an abnormality suggestive of malignancy or current
                       active infection, including TB.

                    -  have received any specified prohibited treatment more recently than the
                       indicated washout period prior to Screening;

                    -  who are participating in any other clinical study or who have received
                       treatment with any investigational drug or device within 3 months prior
                       Screening;

                    -  who is part of the staff or a family member of the staff personnel directly
                       involved with this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </removed_countries>
  <results_reference>
    <citation>Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014 Feb;146(2):392-400.e3.</citation>
    <PMID>24512909</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2007</study_first_submitted>
  <study_first_submitted_qc>September 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2007</study_first_posted>
  <results_first_submitted>November 11, 2011</results_first_submitted>
  <results_first_submitted_qc>November 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2011</results_first_posted>
  <disposition_first_submitted>February 10, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 10, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 14, 2011</disposition_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>2 participants were randomized but not treated. Part 1: 237 participants received ≥1 dose study medication. Part 2: Of 108 enrolled/randomized participants, 95 continued assigned treatment from Part 1 and 13 were randomized and entered into Part 2 of the study (10 participants from Part 1 and 3 participants who were enrolled directly into Part 2).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Infliximab (IFX)</title>
          <description>IFX 5 mg/kg Intravenous (IV) infusions administered at Weeks 0, 2, and 6 and placebo to AZA (orally) daily for 16 weeks. Responders to IFX at Week 8, will receive one more IFX infusion at Week 14; non-responders to IFX will receive placebo infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14.</description>
        </group>
        <group group_id="P2">
          <title>Azathioprine (AZA)</title>
          <description>AZA 2.5 mg/kg orally for 16 weeks and placebo to IFX infusion at Weeks 0, 2, and 6. Responders to AZA monotherapy at Week 8 will continue on AZA therapy and receive one placebo IFX infusion at Week 14; non-responders to AZA at Week 8 will be eligible to receive IFX at Weeks 8, 10, and 14. This group included 20 participants who did not respond to AZA monotherapy at Week 8 had IFX added to their treatment regimen at Weeks 8, 10, and 14.</description>
        </group>
        <group group_id="P3">
          <title>IFX/AZA</title>
          <description>IFX 5 mg/kg IV infusion at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally daily for 16 weeks.
Responders to IFX/AZA at Week 8 will receive one more IFX infusion at Week 14; non-responders to IFX/AZA will receive placebo IFX infusions at Weeks 8 and 10 and one additional IFX infusion at Week 14.</description>
        </group>
        <group group_id="P4">
          <title>Maintenance IFX/AZA (During Part 2)</title>
          <description>Participants randomized to maintenance IFX/AZA received IFX 5 mg/kg of body weight every 8 weeks (beginning at Week 22, Week 6 for direct entry) plus AZA 2.5 mg/kg of body weight daily in Part 2 of the study (4 participants from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study).</description>
        </group>
        <group group_id="P5">
          <title>Maintenance IFX (During Part 2)</title>
          <description>Participants randomized to maintenance IFX received infusion of IFX 5 mg/kg of body weight every 8 weeks (beginning at Week 22, Week 6 for direct entry) and placebo to AZA therapy as allocated in Part 1 of the study (all participants were from Part 1 of the study).</description>
        </group>
        <group group_id="P6">
          <title>Intermittent IFX/AZA (During Part 2)</title>
          <description>Participants randomized to intermittent IFX/AZA received IFX 5 mg/kg of body weight only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained) plus AZA 2.5 mg/kg of body weight daily in Part 2 of the study (3 participants from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study).</description>
        </group>
        <group group_id="P7">
          <title>Intermittent IFX (During Part 2)</title>
          <description>Participants randomized to intermittent IFX received IFX 5 mg/kg of body weight only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained) and placebo to AZA as allocated in Part 1 of the study (1 participant from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol defined clinical event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Never entered follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infliximab (IFX)</title>
          <description>All treated participants. IFX 5 mg/kg IV infusions administered at Weeks 0, 2, and 6 and placebo to AZA daily for 16 weeks. Responders to IFX at Week 8, will receive one more IFX infusion at Week 14; non-responders to IFX will receive placebo infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14.</description>
        </group>
        <group group_id="B2">
          <title>Azathioprine (AZA)</title>
          <description>All treated participants. AZA 2.5 mg/kg orally for 16 weeks and placebo to IFX infusion at Weeks 0, 2, and 6. Responders to AZA monotherapy at Week 8 will continue on AZA therapy and receive one infliximab placebo infusion at Week 14; non-responders to AZA at Week 8 will be eligible to receive infliximab at Weeks 8, 10, and 14. This group included 20 participants who did not respond to AZA monotherapy at Week 8 had IFX added to their treatment regimen at Weeks 8, 10, and 14.</description>
        </group>
        <group group_id="B3">
          <title>IFX/AZA</title>
          <description>All treated participants. IFX 5 mg/kg IV at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally daily for 16 weeks.
Responders to IFX/AZA at Week 8 will receive one more infliximab infusion at Week 14; non-responders to IFX/AZA will receive placebo IFX infusions at Weeks 8 and 10 and one additional IFX infusion at Week 14.</description>
        </group>
        <group group_id="B4">
          <title>Maintenance IFX/AZA (During Part 2)</title>
          <description>Participants enrolled directly and randomized to maintenance IFX/AZA received IFX 5 mg/kg of body weight every 8 weeks (beginning at Week 22, Week 6 for direct entry) plus AZA 2.5 mg/kg of body weight daily in Part 2 of the study (4 participants from Part 1 of the study and 1 participant enrolled directly into Part 2 of the study).</description>
        </group>
        <group group_id="B5">
          <title>Intermittent IFX/AZA (During Part 2)</title>
          <description>Participants enrolled directly and randomized to intermittent IFX/AZA received IFX 5 mg/kg of body weight only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained) plus AZA 2.5 mg/kg of body weight daily in Part 2 of the study (3 participants from Part 1 of the study and 1 participant enrolled directly into Part 2 of the study).</description>
        </group>
        <group group_id="B6">
          <title>Intermittent IFX (During Part 2)</title>
          <description>Participants enrolled directly and randomized to intermittent IFX received IFX 5 mg/kg of body weight only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained) and placebo to AZA daily in Part 2 of the study (1 participant from Part 1 of the study and 1 participant enrolled directly into Part 2 of the study).</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="1"/>
            <count group_id="B6" value="1"/>
            <count group_id="B7" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Baseline characteristics for Part 2 are presented for the direct entry participants only: 1 participant randomized to the maintenance IFX/AZA group, 1 participant randomized to the intermittent IFX/AZA group, and 1 participant randomized to the intermittent IFX group. No participants were directly enrolled into the maintenance IFX group in Part 2 of the study.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 years to &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 years and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Baseline characteristics for Part 2 are presented for the direct entry participants only: 1 participant randomized to the maintenance IFX/AZA group, 1 participant randomized to the intermittent IFX/AZA group, and 1 participant randomized to the intermittent IFX group. No participants were directly enrolled into the maintenance IFX group in Part 2 of the study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants in Steroid-free Remission at Week 16</title>
        <description>Steroid-free remission is defined as a total Mayo score of 2 points or lower, with no individual sub-score exceeding 1 point, without the use of corticosteroids. The total Mayo score consists of the following 4 sub-scores: stool frequency, rectal bleeding, findings of endoscopy (sigmoidoscopy), and physician’s global assessment.</description>
        <time_frame>16 weeks</time_frame>
        <population>Full Analysis Set (participants who were randomized, received at least one dose of study treatment, and had data available for baseline and at least one post baseline evaluation). Participants who dropped out prior to Week 16, had a missing Mayo score at Week 16, or were non-responders at Week 8 are considered failures (non-remission) at Week 16.</population>
        <group_list>
          <group group_id="O1">
            <title>Infliximab (IFX)</title>
            <description>IFX 5 mg/kg IV infusions administered at Weeks 0, 2, and 6 and placebo to AZA daily for 16 weeks. Responders to IFX at Week 8, will receive one more IFX infusion at Week 14; non-responders to IFX will receive placebo infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14.</description>
          </group>
          <group group_id="O2">
            <title>Azathioprine (AZA)</title>
            <description>AZA 2.5 mg/kg orally for 14 weeks and placebo to IFX infusion at Weeks 0, 2, and 6. Responders to AZA monotherapy at Week 8 will continue on AZA therapy and receive one infliximab placebo infusion at Week 14; non-responders to AZA at Week 8 will be eligible to receive infliximab at Weeks 8, 10, and 14. This group included 20 subjects who did not respond to AZA monotherapy at Week 8 had IFX added to their treatment regimen at Weeks 8, 10, and 14.</description>
          </group>
          <group group_id="O3">
            <title>IFX/AZA</title>
            <description>IFX 5 mg/kg IV at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally daily for 16 weeks.
Responders to IFX/AZA at Week 8 will receive one more infliximab infusion at Week 14; non-responders to IFX/AZA will receive placebo infusions at Weeks 8 and 10 and one additional infliximab infusion at Week 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants in Steroid-free Remission at Week 16</title>
          <description>Steroid-free remission is defined as a total Mayo score of 2 points or lower, with no individual sub-score exceeding 1 point, without the use of corticosteroids. The total Mayo score consists of the following 4 sub-scores: stool frequency, rectal bleeding, findings of endoscopy (sigmoidoscopy), and physician’s global assessment.</description>
          <population>Full Analysis Set (participants who were randomized, received at least one dose of study treatment, and had data available for baseline and at least one post baseline evaluation). Participants who dropped out prior to Week 16, had a missing Mayo score at Week 16, or were non-responders at Week 8 are considered failures (non-remission) at Week 16.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22"/>
                    <measurement group_id="O2" value="0.24"/>
                    <measurement group_id="O3" value="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Remission Rate During Part 2 of the Study</title>
        <description>Due to the early termination of this study, evaluations of efficacy were not conducted for Part 2 of the study (Week 38 through Week 94 [Week 22 through Week 78 for direct entry]).</description>
        <time_frame>up to Week 94 (Week 78 for direct entry)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants in Response at Weeks 8 and 16</title>
        <description>Response at Week 8 is defined as a decrease in the partial Mayo score of ≥1 point. Response at Week 16 is defined as a decrease in total Mayo score of ≥3 points and at least 30% lower than baseline Mayo score. The partial Mayo score consists of the following 3 sub-scores: stool frequency, rectal bleeding, and physician’s global assessment. The total Mayo score consists of the following 4 sub-scores: stool frequency, rectal bleeding, findings of endoscopy (sigmoidoscopy), and physician’s global assessment.</description>
        <time_frame>Weeks 8 and 16</time_frame>
        <population>Full Analysis Set (participants who were randomized, received at least one dose of study treatment, and had data available for baseline and at least one post baseline evaluation). Participants who dropped out prior to Week 16, had a missing Mayo score at Week 16, or were non-responders at Week 8 are considered failures (non-responders) at Week 16.</population>
        <group_list>
          <group group_id="O1">
            <title>Infliximab (IFX)</title>
            <description>IFX 5 mg/kg IV infusions administered at Weeks 0, 2, and 6 and placebo to AZA daily for 16 weeks. Responders to IFX at Week 8, will receive one more IFX infusion at Week 14; non-responders to IFX will receive placebo infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14.</description>
          </group>
          <group group_id="O2">
            <title>Azathioprine (AZA)</title>
            <description>AZA 2.5 mg/kg orally for 14 weeks and placebo to IFX infusion at Weeks 0, 2, and 6. Responders to AZA monotherapy at Week 8 will continue on AZA therapy and receive one infliximab placebo infusion at Week 14; non-responders to AZA at Week 8 will be eligible to receive infliximab at Weeks 8, 10, and 14. This group included 20 subjects who did not respond to AZA monotherapy at Week 8 had IFX added to their treatment regimen at Weeks 8, 10, and 14.</description>
          </group>
          <group group_id="O3">
            <title>IFX/AZA</title>
            <description>IFX 5 mg/kg IV at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally daily for 16 weeks.
Responders to IFX/AZA at Week 8 will receive one more infliximab infusion at Week 14; non-responders to IFX/AZA will receive placebo infusions at Weeks 8 and 10 and one additional infliximab infusion at Week 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants in Response at Weeks 8 and 16</title>
          <description>Response at Week 8 is defined as a decrease in the partial Mayo score of ≥1 point. Response at Week 16 is defined as a decrease in total Mayo score of ≥3 points and at least 30% lower than baseline Mayo score. The partial Mayo score consists of the following 3 sub-scores: stool frequency, rectal bleeding, and physician’s global assessment. The total Mayo score consists of the following 4 sub-scores: stool frequency, rectal bleeding, findings of endoscopy (sigmoidoscopy), and physician’s global assessment.</description>
          <population>Full Analysis Set (participants who were randomized, received at least one dose of study treatment, and had data available for baseline and at least one post baseline evaluation). Participants who dropped out prior to Week 16, had a missing Mayo score at Week 16, or were non-responders at Week 8 are considered failures (non-responders) at Week 16.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88"/>
                    <measurement group_id="O2" value="0.66"/>
                    <measurement group_id="O3" value="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69"/>
                    <measurement group_id="O2" value="0.50"/>
                    <measurement group_id="O3" value="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Mucosal Healing at Week 16</title>
        <description>Mucosal healing was defined as a Mayo endoscopy score of 0 or 1.</description>
        <time_frame>16 weeks</time_frame>
        <population>Full Analysis Set (participants who were randomized, received at least one dose of study treatment, and had data available for baseline and at least one post baseline evaluation).</population>
        <group_list>
          <group group_id="O1">
            <title>Infliximab (IFX)</title>
            <description>IFX 5 mg/kg IV infusions administered at Weeks 0, 2, and 6 and placebo to AZA daily for 16 weeks. Responders to IFX at Week 8, will receive one more IFX infusion at Week 14; non-responders to IFX will receive placebo infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14.</description>
          </group>
          <group group_id="O2">
            <title>Azathioprine (AZA)</title>
            <description>AZA 2.5 mg/kg orally for 14 weeks and placebo to IFX infusion at Weeks 0, 2, and 6. Responders to AZA monotherapy at Week 8 will continue on AZA therapy and receive one infliximab placebo infusion at Week 14; non-responders to AZA at Week 8 will be eligible to receive infliximab at Weeks 8, 10, and 14. This group included 20 subjects who did not respond to AZA monotherapy at Week 8 had IFX added to their treatment regimen at Weeks 8, 10, and 14.</description>
          </group>
          <group group_id="O3">
            <title>IFX/AZA</title>
            <description>IFX 5 mg/kg IV at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally daily for 16 weeks.
Responders to IFX/AZA at Week 8 will receive one more infliximab infusion at Week 14; non-responders to IFX/AZA will receive placebo infusions at Weeks 8 and 10 and one additional infliximab infusion at Week 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Mucosal Healing at Week 16</title>
          <description>Mucosal healing was defined as a Mayo endoscopy score of 0 or 1.</description>
          <population>Full Analysis Set (participants who were randomized, received at least one dose of study treatment, and had data available for baseline and at least one post baseline evaluation).</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55"/>
                    <measurement group_id="O2" value="0.37"/>
                    <measurement group_id="O3" value="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Who Are in Steroid-free Remission During Part 2 of the Study</title>
        <description>Due to the early termination of this study, evaluations of efficacy were not conducted for Part 2 of the study.</description>
        <time_frame>Weeks 38, 62 &amp; 94 (Weeks 22, 46 and 78 for direct entry)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Mucosal Healing During Part 2 of the Study</title>
        <description>Due to the early termination of this study, evaluations of efficacy were not conducted for Part 2 of the study</description>
        <time_frame>Weeks 38, 62 and 94 (Weeks 22, 46 and 78 for direct entry)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were categorized by 3 separate timeframes: Through Week 8 (AEs reported through Week 8 of Part 1), After Week 8 (AEs reported after Week 8 through Week 16 of Part 1), and Part 2 (AEs reported during Part 2)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AZA Through Week 8</title>
          <description>Participants received AZA 2.5 mg/kg orally daily for 16 weeks. Responders to AZA monotherapy at Week 8 will continue on AZA therapy and receive one infliximab placebo infusion at Week 14; non-responders to AZA at Week 8 will be eligible to receive infliximab at Weeks 8, 10, and 14.</description>
        </group>
        <group group_id="E2">
          <title>IFX/AZA Through Week 8</title>
          <description>Participants received intravenous (IV) infusions of IFX 5 mg/kg of body weight at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally daily for 16 weeks.
Responders to IFX/AZA at Week 8 will receive one more infliximab infusion at Week 14; nonresponders to IFX/AZA will receive placebo infusions at Weeks 8 and 10 and one additional infliximab infusion at Week 14.</description>
        </group>
        <group group_id="E3">
          <title>IFX Through Week 8</title>
          <description>Participants received IV infusions of IFX 5 mg/kg of body weight administered at Weeks 0, 2, and 6. Responders to IFX at Week 8, will receive one more IFX infusion at Week 14; non-responders to IFX will receive placebo infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14.</description>
        </group>
        <group group_id="E4">
          <title>AZA After Week 8</title>
          <description>Participants received AZA 2.5 mg/kg orally daily for 16 weeks. Responders to AZA monotherapy at Week 8 will continue on AZA therapy and receive one infliximab placebo infusion at Week 14; non-responders to AZA at Week 8 will be eligible to receive infliximab at Weeks 8, 10, and 14.</description>
        </group>
        <group group_id="E5">
          <title>AZA to IFX/AZA After Week 8</title>
          <description>Participants received AZA 2.5 mg/kg orally for 16 weeks and had IV infusions of IFX 5mg/kg of body weight added to their treatment regimen at Weeks 8, 10, and 14. Participants were either non-responders to AZA at Week 8 or had worsening of disease at Week 8.</description>
        </group>
        <group group_id="E6">
          <title>IFX/AZA After Week 8</title>
          <description>Participants received IV infusions of IFX 5 mg/kg of body weight at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally daily for 16 weeks.
Responders to IFX/AZA at Week 8 will receive one more infliximab infusion at Week 14; nonresponders to IFX/AZA will receive placebo infusions at Weeks 8 and 10 and one additional infliximab infusion at Week 14.</description>
        </group>
        <group group_id="E7">
          <title>IFX After Week 8</title>
          <description>Participants received IV infusions of IFX 5 mg/kg of body weight administered at Weeks 0, 2, and 6. Responders to IFX at Week 8, will receive one more IFX infusion at Week 14; non-responders to IFX will receive placebo infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14.</description>
        </group>
        <group group_id="E8">
          <title>Maintenance IFX/AZA (Part 2)</title>
          <description>Participants randomized to maintenance IFX/AZA during Part 2 received IV infusion of IFX 5 mg/kg of body weight every 8 weeks (beginning at Week 22, Week 6 for direct entry) plus AZA 2.5 mg/kg of body weight daily. Four participants were from Part 1 of the study and 1 participant enrolled directly into Part 2 of the study.</description>
        </group>
        <group group_id="E9">
          <title>Maintenance IFX (Part 2)</title>
          <description>Participants randomized to maintenance IFX received IV infusions of IFX 5 mg/kg of body weight every 8 weeks (beginning at Week 22, Week 6 for direct entry). All participants were from Part 1 of the study.</description>
        </group>
        <group group_id="E10">
          <title>Intermittent IFX/AZA (Part 2)</title>
          <description>Participants randomized to intermittent IFX/AZA received IV infusions of IFX 5 mg/kg of body weight only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained) plus AZA 2.5 mg/kg of body weight daily. Three participants were from Part 1 of the study and 1 participant enrolled directly into Part 2 of the study.</description>
        </group>
        <group group_id="E11">
          <title>Intermittent IFX (Part 2)</title>
          <description>Participants randomized to intermittent IFX received IV infusions of IFX 5 mg/kg of body weight only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained). One participant from Part 1 of the study and 1 participant enrolled directly into Part 2 of the study.</description>
        </group>
        <group group_id="E12">
          <title>AZA (Part 2)</title>
          <description>Participants received AZA 2.5 mg/kg of body weight orally daily for Part 2 of the study. All participants were from Part 1 of the study.</description>
        </group>
        <group group_id="E13">
          <title>IFX/AZA (Part 2)</title>
          <description>Participants received IV infusions of IFX 5 mg/kg of body weight every 8 weeks and AZA 2.5 mg/kg of body weight orally daily until the end of the study. All participants were from Part 1 of the study.</description>
        </group>
        <group group_id="E14">
          <title>IFX (Part 2)</title>
          <description>Participants received IV infusions of IFX 5 mg/kg of body weight until the end of the study. All participants were from Part 1 of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 13.0">Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 13.0">Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Colitis Ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Intestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Drug Ineffective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Aspergillosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Ileostomy closure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Intestinal Anastomosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Proctocolectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="48"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Iron deficiency anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="10" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Colitis Ulcerative</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="5" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="5" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to release and can embargo communications regarding trial results for a period that is less than or equal to 45 days from the time submitted to the sponsor for review. If the parties disagree on the communication, the investigator and sponsor's representative will meet for the purpose of making a good faith effort to discuss and resolve any such issues or disagreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

